Changes in Hong Kong stocks | Insili Smart (03696) rose more than 10% to announce formal R&D cooperation with Yuancode Intelligent Pharmaceutical to forward-looking layout of next-generation mRNA oncology vaccines

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that Insili Intelligence (03696) rose by more than 10%. As of press release, it had risen 10.5% to HK$43.62, with a turnover of HK$1,544 billion.

According to news, on August 20, the company announced today that it has officially reached a research and development cooperation with Byterna Therapeutics (Byterna Therapeutics), which focuses on developing next-generation RNA innovative drugs. The two sides will focus on AI new antigen prediction and sequence design, cyclic mRNA, targeted delivery, automated experiments, and intelligent manufacturing to jointly build a next-generation mRNA AI native R&D engine to explore individualized tumor vaccines and related innovative therapies.

Insili Smart and Metacode Intelligence focus their differentiation on cyclic mRNAs. Compared with traditional linear mRNAs, cyclic mRNAs have research potential in terms of molecular stability and continuous expression due to their closed loop structure. Yuancode Intelligent Medicine has established technology accumulation around cyclic mRNA molecule design, cyclic engineering, chemical modification, tLNP targeted delivery, production and purification, and CMC, with the aim of improving developability and making the risk of innate immune activation more manageable.